PRQR - ProQR Therapeutics N.V.
| Previous Close | 3.58 |
| Open | 3.65 |
| Bid | 2.80 x 100 |
| Ask | 4.00 x 1000 |
| Day's Range | 3.50 - 3.70 |
| 52 Week Range | 2.75 - 6.90 |
| Volume | 43,212 |
| Avg. Volume | 80,174 |
| Market Cap | 113.104M |
| Beta | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings Date | May 15, 2018 - May 21, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.13 |
- Zacks•4 days ago
Will ProQR Therapeutics (PRQR) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in ProQR Therapeutics N.V. (PRQR)
- GlobeNewswire•12 days ago
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
Peter A. Beal joins ProQR’ s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field ...
- GlobeNewswire•19 days ago
ProQR to Present at Two Upcoming Conferences
LEIDEN, the Netherlands, April 03, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
- GlobeNewswire•2 months ago
ProQR to Present at Upcoming Investor Conference
LEIDEN, the Netherlands, March 05, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
- Associated Press•2 months ago
ProQR reports 4Q loss
The Leiden, Netherlands-based company said it had a loss of 46 cents per share. For the year, the company reported that its loss widened to $49.3 million, or $1.94 per share. The company's shares closed ...
- GlobeNewswire•2 months ago
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase ...
- GlobeNewswire•2 months ago
ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
LEIDEN, the Netherlands, Feb. 27, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
- Simply Wall St.•2 months ago
Where ProQR Therapeutics NV. (NASDAQ:PRQR) Stands In Terms Of Earnings Growth Against Its Industry
After looking at ProQR Therapeutics NV.’s (NASDAQ:PRQR) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...
- GlobeNewswire•2 months ago
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2 A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness ...
- Market Realist•2 months ago
How Did Kalydeco Perform in 4Q17 and 2017?
How Is Vertex Pharmaceuticals Positioned after 4Q17?
- GlobeNewswire•2 months ago
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
LEIDEN, the Netherlands, Feb. 06, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases ...
- Associated Press•5 months ago
ProQR reports 3Q loss
On a per-share basis, the Leiden, Netherlands-based company said it had a loss of 49 cents. The company's shares closed at $3.10. A year ago, they were trading at $4.75. _____ This story was generated ...
